....to Prevent Disability
SUMMARY
A study based at Johns Hopkins University is comparing two treatment strategies in 900 people newly diagnosed, or with onset/diagnosis in the past who have received minimal or no treatment, with the relapsing-remitting form of MS. The study is recruiting at approximately 45 centers nationwide. One option is an escalation approach, in which patients start taking a less-powerful therapy with the option of switching to a more potent therapy if disease activity continues. The other approach involves starting with a stronger therapy that is potentially more effective, but also carries the potential for greater risk for significant adverse effects. The “TRaditional versus Early Aggressive Therapy for Multiple Sclerosis” (TREAT-MS) Trial is funded by the Patient-Centered Outcomes Research Institute (PCORI).
Transcript: Ask Me Anything with Dr. Barry Singer
Research Study on COVID-19 Vaccines in People with MS
I'm New Here, But Not to MS
Should Ocrevus Begin Listing Hair Loss as a Potential Side Effect?
